Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica

被引:62
作者
Wang, SS
Schiffman, M
Herrero, R
Carreon, J
Hildesheim, A
Rodriguez, AC
Bratti, MC
Sherman, ME
Morales, J
Guillen, D
Alfaro, M
Clayman, B
Burk, RD
Viscidi, RP
机构
[1] NCI, Hormonal & Reprod Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA
[2] Proyecto Epidemiol Guanacaste, San Jose, Costa Rica
[3] Albert Einstein Coll Med, Bronx, NY 10461 USA
[4] Johns Hopkins Univ, Sch Med, Dept Pediat, Stanley Div Dev Neurovirol, Baltimore, MD 21205 USA
关键词
HPV; serology; persistence; conversion; cervix; cancer;
D O I
10.1038/sj.bjc.6602088
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Determinants of human papillomavirus (HPV)-16 serological conversion and persistence were assessed in a population-based cohort of 10 049 women in Guanacaste, Costa Rica. Serologic responses to HPV-16 were measured in 7986 women by VLP-based enzyme-linked immunosorbent assay at both study enrolment (1993/94) and at 5-7 years of follow-up. Seropositive women were defined as greater than or equal to5 standard deviations above the mean optical density obtained for studied virgins at enrolment (n=573). Seroconnversion (n=409), persistence (n=675), and clearance (n=541) were defined based on enrolment and follow-up serology measurements. Age-specific distributions revealed that HPV-16 seroconversion was highest among 18- to 24-year-old women, steadily declining with age; HPV-16 seropersistence was lowest in women 65+ years. In age-adjusted multivariate logistic regression models, a 10-fold risk increase for HPV-16 seroconversion was associated with HPV-16 DNA detection at enrolment and follow-up; two-fold risk of seroconversion to HPV-16 was associated with increased numbers of lifetime and recent sexual partners and smoking status. Determinants of HPV-16 seropersistence included a 1.5-fold risk increase associated with having one sexual partner during follow-up, former oral contraceptive use, and a 3-fold risk increase associated with HPV-16 DNA detection at both enrolment and follow-up. Higher HPV-16 viral load at enrolment was associated with seroconversion, and higher antibody titres at enrolment were associated with seropersistence.
引用
收藏
页码:1269 / 1274
页数:6
相关论文
共 35 条
[1]  
af Geijersstam V, 1998, J INFECT DIS, V177, P1710, DOI 10.1086/517428
[2]  
Bratti MC, 2004, REV PANAM SALUD PUBL, V15, P75
[3]   The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women [J].
Carter, JJ ;
Koutsky, LA ;
Wipf, GC ;
Christensen, ND ;
Lee, SK ;
Kuypers, J ;
Kiviat, N ;
Galloway, DA .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (05) :927-936
[4]   Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection [J].
Carter, JJ ;
Koutsky, LA ;
Hughes, JP ;
Lee, SK ;
Kuypers, J ;
Kiviat, N ;
Galloway, DA .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (06) :1911-1919
[5]  
Chua KL, 1996, INT J CANCER, V68, P54, DOI 10.1002/(SICI)1097-0215(19960927)68:1<54::AID-IJC11>3.0.CO
[6]  
2-6
[7]   Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer [J].
Dillner, J ;
Lehtinen, M ;
Bjorge, T ;
Luostarinen, T ;
Youngman, L ;
Jellum, E ;
Koskela, P ;
Gislefoss, RE ;
Hallmans, G ;
Paavonen, J ;
Sapp, M ;
Schiller, JT ;
Hakulinen, T ;
Thoresen, S ;
Hakama, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (17) :1293-1299
[8]   Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica [J].
Herrero, R ;
Hildesheim, A ;
Bratti, C ;
Sherman, ME ;
Hutchinson, M ;
Morales, J ;
Balmaceda, I ;
Greenberg, MD ;
Alfaro, M ;
Burk, RD ;
Wacholder, S ;
Plummer, M ;
Schiffman, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (06) :464-474
[9]  
HERRERO R, 1997, PAN AM J PUBLIC HLTH, V1, P362
[10]   HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica [J].
Hildesheim, A ;
Herrero, R ;
Castle, PE ;
Wacholder, S ;
Bratti, MC ;
Sherman, ME ;
Lorincz, AT ;
Burk, RD ;
Morales, J ;
Rodriguez, AC ;
Helgesen, K ;
Alfaro, M ;
Hutchinson, M ;
Balmaceda, I ;
Greenberg, M ;
Schiffman, M .
BRITISH JOURNAL OF CANCER, 2001, 84 (09) :1219-1226